Travere Therapeutics (TVTX) | Stock Overview & Key Data
Travere Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $37.04 on August 3, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics TVTX | 1.35B Small-cap | 10.04% | 9.52% | 13.80% | -9.73% | -13.92% | 56.12% | -37.58% | -26.05% |
| Vertex VRTX | 114.06B Large-cap | 4.80% | 7.35% | -0.69% | 16.95% | 18.04% | -4.58% | 59.25% | 58.34% |
| Regeneron REGN | 55.27B Large-cap | 0.88% | 6.76% | -4.19% | -20.71% | -22.74% | -50.21% | -9.84% | -14.95% |
| Vera Therapeutics VERA | 1.38B Small-cap | 2.37% | 9.10% | 9.95% | -34.60% | -42.63% | -37.19% | 44.20% | 100.00% |
| Immunocore Holdings IMCR | 1.67B Small-cap | 5.59% | -4.13% | 32.39% | 13.75% | 15.96% | -15.77% | -23.05% | -22.96% |
| Agios AGIO | 2.12B Mid-cap | 10.52% | 16.07% | 48.67% | 13.51% | 22.71% | -20.92% | 62.62% | -32.33% |
Ownership & Short Interest
Travere Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Travere Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is TVTX's 52-week high and low?
In the last 52 weeks, Travere Therapeutics reached a high of $25.29 (on February 11, 2025) and a low of $7.93 (on August 5, 2024).
What is the market cap and P/E ratio for TVTX?
Curious about Travere Therapeutics's size and valuation? Its market capitalization stands at 1.35B. When it comes to valuation, the P/E ratio (trailing twelve months) is -3.71, and the forward P/E (looking ahead) is -12.49.
Does TVTX pay dividends? If so, what's the yield?
As for dividends, Travere Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Travere Therapeutics's main competitors or similar companies to consider before investing?
When looking at Travere Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 114.06B | Healthcare | Biotechnology | -4.58% | 59.25% |
| Regeneron REGN | 55.27B | Healthcare | Biotechnology | -50.21% | -9.84% |
| Vera Therapeutics VERA | 1.38B | Healthcare | Biotechnology | -37.19% | 44.20% |
| Immunocore Holdings IMCR | 1.67B | Healthcare | Biotechnology | -15.77% | -23.05% |
| Agios AGIO | 2.12B | Healthcare | Biotechnology | -20.92% | 62.62% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Travere Therapeutics Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Travere Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -422.66%, the Debt to Equity ratio from the most recent quarter is 1,220.07, and its Gross Profit Margin stands at 94.28%.
What is the recent revenue and earnings growth for TVTX?
Looking at Travere Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $274M. Compared to the same quarter last year (YoY), quarterly revenue grew by 97.50%, and quarterly earnings saw a YoY growth of 97.54%.
How much of TVTX stock is held by insiders and institutions?
Wondering who owns Travere Therapeutics stock? Company insiders (like executives and directors) hold about 0.75% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 113.35%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.